Findings from a recent study suggest a possible association between vitamin D and disease severity among patients with psoriasis. For details from the study, including whether vitamin D supplementation is beneficial, read more.

FDA Alerts

FDA Alerts
Monday, October 16, 2017
The FDA has approved an expanded indication for ustekinumab (Stelara; Janssen) for the treatment of adolescent patients 12 years or older with moderate to severe plaque psoriasis.
FDA Alerts
Tuesday, August 29, 2017
The FDA has approved adalimumab-adbm (Cyltezo), a biosimilar of Humira (adalimumab), for the treatment of multiple inflammatory diseases.
FDA Alerts
Friday, July 14, 2017
The FDA has approved an injectable treatment for moderate to severe plaque psoriasis in adult patients.
FDA Alerts
Friday, July 7, 2017
The FDA has approved the intravenous (IV) and subcutaneous injection (SC) formulations of abatacept (Orencia; Bristol-Myers Squibb) for the treatment of active psoriatic arthritis (PsA) in adult patients.

News

News
Friday, March 23, 2018
In a recent study, researchers investigated the long-term efficacy of a psoriasis therapy following withdrawal of treatment among patients with moderate to severe plaque psoriasis.
News
Monday, March 19, 2018
Researchers recently investigated the safety and efficacy of treatment with an interleukin 17A antagonist among patients with psoriatic arthritis.
News
Monday, March 12, 2018
Patients with psoriasis have an increased risk for cardiovascular events. In a recent study, researchers compared the effects of treatment with tumor necrosis factor-alpha inhibitors or phototherapy on this risk.
News
Tuesday, February 20, 2018
The results of a recent study have indicated potential gaps in the treatment of various cardiovascular risk factors in patients with psoriatic disease.

NPF Endorsed Articles

NPF Endorsed Articles
Monday, December 21, 2015
​The prevalence of non-alcoholic fatty liver disease (NAFLD) in psoriasis patients was evaluated in a cross-sectional study, recently published in Journal of the European Academy of Dermatology and Venereology. 
NPF Endorsed Articles
Friday, December 18, 2015
Dermira, Inc., a specialty biopharmaceutical company, announced the completion of patient enrollment for the global CIMPASI-1 clinical trial of certolizumab pegol (Cimzia, UCB Inc.) in adult patients with moderate-to-severe chronic plaque psoriasis.
NPF Endorsed Articles
Friday, December 18, 2015
New research finds the incidence of psoriatic arthritis (PsA) among patients with psoriasis is much greater than previously thought.
NPF Endorsed Articles
Friday, December 18, 2015
  This article reviews the current biologic therapies for the treatment of psoriasis and psoriatic arthritis, discusses the importance of patient and clinician education in the decision-making process and highlights drugs in the pipeline.

Research in Review

Research in Review
Thursday, November 16, 2017
The condition is characterized by an acute, subacute, or chronic eruption of sterile pustules associated with erythema and inflammation. This patient’s case represents the annular variant characterized by pustules on the periphery of expanding erythematous plaques with central healing, most often localized to the trunk.
Research in Review
Friday, September 8, 2017
Starting a support group for patients with psoriasis has many benefits and some challenges, too.
Research in Review
Wednesday, August 9, 2017
Kaiser Permanente researcher and clinician has studied how inflammatory effects of psoriasis can impact the entire body.
Research in Review
Monday, July 3, 2017
In this case, a 37-year-old man presented to the clinic seeking continuing care for a chronic, pruritic, bilateral rash. On physical examination, well-defined erythematous patches and papules with overlying scale were present on the anterior and posterior portion of the lower extremities.